SCGN and Alzheimer disease: In severe Alzheimer’s disease subjects (Braak V–VI), we identified a parallel decrease in TH (relative fluorescence intensity values: 103.59 ± 5.82 in Braak I–II vs. 52.66 ± 1.55 in Braak V–VI) and secretagogin (relative fluorescence intensity values: 47.13 ± 0.03 in Braak I–II vs. 27.42 ± 1.06 in Braak V–VI) immunoreactivity (Fig. 8e–g’’).